Prellis is dedicated to building tissues to eliminate the organ transplant waitlist.

Our mission is to use novel tissue engineering technology to advance human health.

What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





What distinguishes Prellis from other tissue engineering companies?


By combining expertise in the Chemistry, Optical Engineering, Microfluidics, Cell Biology, and Software development spaces, Prellis has developed a full-stack process and platform for end-to-end tissue development starting with high-resolution 3D design engineering and ending with bioreactor-based tissue maturation.
Prellis is already answering questions that other tissue engineering endeavors have yet to answer around basic capillary flow network design and engineering for organ compatibility. Our process is an end-to-end approach that produces ultrafast tissue scaffolds.





prellis-white-icon-01.png
prellis-white-icon-01.png

What distinguishes Prellis from other tissue engineering companies?


By combining expertise in the Chemistry, Optical Engineering, Microfluidics, Cell Biology, and Software development spaces, Prellis has developed a full-stack process and platform for end-to-end tissue development starting with high-resolution 3D design engineering and ending with bioreactor-based tissue maturation.
Prellis is already answering questions that other tissue engineering endeavors have yet to answer around basic capillary flow network design and engineering for organ compatibility. Our process is an end-to-end approach that produces ultrafast tissue scaffolds.





Why is Prellis active in the therapeutics space?


On the way to bioprinting large organs for transplantation, Prellis has built and validated smaller test-tissues including human lymph nodes and human liver. Prellis-engineered human tissues are able to replicate in vivo human processes without needing to access a human patient. Using exclusively Prellis technology, we are able to provide the first human synthetic tissue for drug discovery and testing. Our synthetic human tissue provides consistent access to functional human biology outside of the human test subjects, so the possibilities for accelerating accurate drug discovery and testing are endless.





What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





prellis-white-icon-01.png

What distinguishes Prellis from other tissue engineering companies?


By combining expertise in the Chemistry, Optical Engineering, Microfluidics, Cell Biology, and Software development spaces, Prellis has developed a full-stack process and platform for end-to-end tissue development starting with high-resolution 3D design engineering and ending with bioreactor-based tissue maturation.
Prellis is already answering questions that other tissue engineering endeavors have yet to answer around basic capillary flow network design and engineering for organ compatibility. Our process is an end-to-end approach that produces ultrafast tissue scaffolds.





prellis-white-icon-01.png
prellis-white-icon-01.png
prellis-white-icon-01.png

What distinguishes Prellis from other tissue engineering companies?


By combining expertise in the Chemistry, Optical Engineering, Microfluidics, Cell Biology, and Software development spaces, Prellis has developed a full-stack process and platform for end-to-end tissue development starting with high-resolution 3D design engineering and ending with bioreactor-based tissue maturation.
Prellis is already answering questions that other tissue engineering endeavors have yet to answer around basic capillary flow network design and engineering for organ compatibility. Our process is an end-to-end approach that produces ultrafast tissue scaffolds.





prellis-white-icon-01.png
_kidney_rotate-min.gif